Effects of ivermectin with and without doxycycline on clinical symptoms of onchocerciasis

Journal of the College of Physicians and Surgeons Pakistan

Volumn 19, Issue 1, 2009, Pages 34-38

  Masud, Hannan ^a   Qureshi, Tausif Qadir ^a   Dukley, Meimei ^b  

^a Peshawar Cantonment   (Pakistan)

^b Ministry of Health and Social Welfare   (Liberia)

Author keywords

African river blindness; Black fly; Blinding filariasis; Doxycycline; Ivermectin; Microfilariae; Onchocerca volvulus; Simulium dansonum

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; IVERMECTIN; STEROID;

ADULT; ARTICLE; BIOMICROSCOPY; CHI SQUARE TEST; CHORIORETINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HUMAN; IRIDOCYCLITIS; KERATITIS; LIBERIA; MAJOR CLINICAL STUDY; MALE; NEGRO; OCULAR PRURITUS; ONCHOCERCIASIS; OPTIC NERVE ATROPHY; PANNUS; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SLIT LAMP; SUBCUTANEOUS NODULE; SYMPTOMATOLOGY; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ANTIPARASITIC AGENTS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IVERMECTIN; LIBERIA; MALE; MIDDLE AGED; ONCHOCERCIASIS, OCULAR; PROSPECTIVE STUDIES;

EID: 63049085491     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organization. Onchocerciasis and its control. World Health Organ Tech Rep Ser 1995; 852:1-103.
2. Hoerauf A, Buttner DW, Adjel O, Pearlman E. Science, medicine, anal the future. Onchocerciasis. BMJ 2003; 326:207-10.
3. Little M, Brietling L, Basáñez MG, Alley E, Boatin B. Association between microfilarial load and excess mortality in Onchocerciasis: an epidemiological study. Lancet 2004; 363: 1514-21.
4. Okulicz JF, Elston DM, Schwartz RA. Onchocemiasis (river blindness). In: Belsito D, Butler DF, Meffert J, Quirk C, James WD, (edi). eMedicine World Library [online]. Last updated: January 5, 2007. [Cited on May 20, 2007]. Available from: URL: http://www.emedcine.com/derm/topic637.htm.
5. Remme JHF. Research for control: the onchocerciasis experience. Trop Med Int Health 2004; 9: 2.
6. Duke BO. The population dynamics of Onchocerca volvulus in the human host. Trop Med Parasitol 1993; 44:61-8.
7. Boatin BA, Toé L, Alley ES, Dembélé N, Weiss N, Dadzie KY. Diagnostics in onchocerciasis: future challenges. Ann Trop Med Parasitol 1998; 92:S41-5.
8. Toé L, Boatin BA, Adjami A, Back C, Merriweather A, Unnasch TR. Detection of Onchocerca volvulus infection by 0-150 polymerase chain reaction analysis of skin scratches. J Infect Dis 1998; 178:282-5.
9. Weil G J, Steel C, Liftis F, Li BW, Mearns G, Lobos E, Nutman TB. A rapid-format antibody card test for diagnosis of onchocerciasis. J Infect Dis 2000; 182:1796-9.
10. Ayong LS, Tume CB, Wembe FE, Simo G, Asonganyi T, Lando G, et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop Med Int Health 2005; 10:228-33.
11. Dadzie KY, Bird AC, Awadzi K, Schulz-Key H, Gilles HM, Aziz MA. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br J Ophthalmology 1987; 71:78-85.
12. Tielsch JM, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health 2004; 9:A45-56.
13. Richards F, Hopkins D, Cupp E. Programmatic goals and approaches to onchocerciasis. Lancet 2000; 355:1663-4.
14. Abiose A, Homeida M, Liese B, Molyneux D, Remme H. Onchocerciasis control strategies, Lancet 2000; 356:1523-4.
15. Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autennieth IB, Fleischer B, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242-3.
16. Hoerauf A, Maud S, Adjei O. Fleischer B, Buttner DW. Depletion of Wolbacbia endobacteria in Oncbocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001; 357:1415-6.
17. Cline BL, Hernandez JL, Mather FJ, Bartholomew R, De Maza SN, Rodulfo S, et al. Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela. Am J Trap Med Hyg 1992; 47:512-20
18. Awadzi K, Addy ET, Opoku NO, Plenge-Bönig A, Büttner DW. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole. Trop Med Pamsitol 1995; 46:213-20.
19. Burkhart CN. Ivermectin: an assessment of its pharmacology, microbiology and safety. Vet Euro Toxicol 2000; 42:30-5.
20. Goa K, Mc Tavish D, Clissold S. Ivermectin: a review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs 1991; 42:640-58.
21. Awadzi K. Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis, Filaria J 2003; 2:S6.
22. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue, Duke BO. Effects of standard and high doses of ivermectin on adult worms of Oncbocerca volvulus: a randomised controlled trial. Lancet 2002; 360:203-10.
23. Taylor M J, Hoerauf A. A new approach to the treatment of filariasis. Curr Opin Infect Dis 2001; 14:727-31.
24. Debrah AY, Mand S, Marfo-Debrekyei Y, Larbi J, Adiei O, Hoerauf A. Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin. Filaria J 2006; 5:1.
25. Arfan-ul-Bari. Clinical spectrum of onchodermatitis. J Coll Physicians Surg Pak 2007; 17:457-61.